February 10, 2023: Revisions have been made to the ACIP General Best Practice Guidelines for Immunization. 

General Best Practice Guidelines for Immunizations

Printer friendly version

To see the revisions, please go to ACIP List of Errata/Updates for Guidelines for Immunization.

2023:

• PAGE 29
• Timing and Spacing of Immunobiologics – Unknown or Uncertain Vaccination Status
• Table 3-1
• Novavax COVID-19 vaccine has been added.
• PAGE 35
• Timing and Spacing of Immunobiologics – Unknown or Uncertain Vaccination Status
• Table 3-2
• A footnote has been added to clarify that if LAIV is administered to a child between the ages of 6 months and 2 years, it is an administration error, but the dose does not need to be repeated.
• PAGE 57
• Contraindications and Precautions
• Table 4-1
• A precaution has been removed for IIV, lowering the threshold to administer IIV: Egg allergy other than hives, e.g., angioedema, respiratory distress, lightheadedness, recurrent emesis; or required epinephrine or another emergency medical intervention (IIV may be administered in an inpatient or outpatient medical setting and under the supervision of a health care provider who is able to recognize and manage severe allergic conditions).
• PAGE 144
• Altered Immunocompetence
• Language was added to the footnote for chronic renal disease to affirm that healthy persons through 59 years of age are recommended for hepatitis B vaccine regardless of whether they have chronic renal disease or not.
• PAGE 194
• Glossary
• The terms Immunization and Vaccination have discrete paragraphs/listings (previously they were both defined in a single paragraph).
• PAGE 32
• Timing and Spacing of Immunobiologics – Unknown or Uncertain Vaccination Status
• Table 3-2
• PCV15 and PCV20 have been added to Table 3-2, with an explanatory footnote.
• PAGE 101
• Vaccine Administration
• Table 6-1
• PCV15 and PCV20 have been added.
• PAGE 120
• Storage and Handling of Immunobiologics
• Table 7-1
• PCV15 and PCV20 have been added
• PAGE 133
• Altered Immunocompetence
• Clarification has been added to guidance involving RZV re-administration to recipients of hematopoietic stem cell transplants (HSCT). More specificity on the timing of vaccination has been provided, on the basis of antiviral timing.